Fidelio acquires Indical Bioscience

April 5, 2018

Fidelio acquires Indical Bioscience, a leading provider of diagnostic products specifically developed for veterinary specific applications.

The company develops and markets diagnostic solutions and products based on PCR (molecular) and ELISA (immunodiagnostic) technology. The products are used by laboratories primarily to indicate and diagnose viruses and bacteria in production animals, to counteract proliferation and contribute to better animal and human health.

Indical Bioscience is based in Germany and serves customers in 169 countries through its own sales force and commercial partners. Fidelio Capital acquired Indical Bioscience through a carve-out from Qiagen, a molecular diagnostic group listed on the NYSE and Frankfurt stock exchanges.

Recent news

Trinity Property Group joins Odevo

Fidelio’s international challenger in the property and housing management industry, Odevo, grows through the addition of Trinity Property Group. Trinity Property Group manages over 95,000 homes across England and Wales and has agreements for an additional 55,000 homes, making the

Read more

Odevo becomes SaaS supplier to leading Swedish pr…

Odevo, an international challenger in the property and housing management industry founded by Fidelio, has entered into an agreement with the housing developer JM. The agreement gives four Swedish management companies, managing a third of Sweden’s homeowner associations, access to

Read more

Odevo grows with fintech company Monu

Founded by Fidelio, Odevo continues to challenge the property and housing management industry. By acquiring the fintech company Monu, Odevo is now taking the step to offer its customers, i.e. property owners and homeowner associations, banking services within saving and

Read more